This is a retrospective, descriptive study with longitudinal follow-up aimed at evaluating the efficacy and tolerability of first-line afatinib treatment in stage IV non-small cell lung cancer (NSCLC) with EGFR mutations at Hanoi Medical University Hospital. Treatments are from January 2018 to June 2021.